Kanglaite combined Gemcitabine inhibits growth of nude mouse subcir taneous transplantation tumor of human PC-3 pancreatic cancer cell


Objective  To study the mechanisms of pancreatic cancer treatment with Kanglaite combined
Gemcitabine by investigating the relationship between the apoptosis and the expression of bcl-2, Bax and
V EGF in pancreatic cancer cells.

Methods  Nude mouse subcutaneous transplantation tumor model of Hu-
man PC-3 pancreatic cancer was established; the expressions of bcl 2, Bax and V EGF of transplantation
tumor cell were determined; the earlier apoptosis rate of pancreatic cancer cell and the gross tumor volume
were determined.

Results Kanglaite combined Gemcitabine remarkably decreased the protein expression of
bcl-2, raised the expression of Bax, increased the apoptosis rate of the pancreatic cancer and contract the
gross tumor volume. Kanglaite greatly decreased the protein expression of V EGF of the tumor cell. Con-
clusion Therapeutic efficacy of Kanglaite combined Gemcitabine is far better than separate use of the two
medicines in the pancreatic cancer transplantation tumor treatment
[Key wordy ] human PC-3 pancreatic cancer; nude mouse subcutaneous transplantation tumor; apopto-
sis; immunohistochemisry; bcl-2; Bax; V EGF

Pancreatic cancer, a rapidly developed disorder, is one of the most common diseases in digestive systems. It is characterized by having no typical symptoms before being diagnosed at the final phase. Known as one of the strongholds in 21st century, the incidence rate of the disease inclines to rise continually. The surgical removal is the only possible choice in radical treatment. Unfortunately, the successful removal rate is about 10%-20% .Therefore, pharmacotherapy falls to be an indispensable means of treatment. Gemcitabine is regarded as a milestone in pancreatic cancer treatment. It is a kind of analogue of arabinosylcytosin and belongs to anticancer drugs of anti-metabolism. It mainly affects on DN A synthesis period and late G phase and produce strong anti-neoplasmic activity through inducing apoptosis. However, some experiments discover that some
pancreatic carcinoma cell tolerances to Gemcitabine gradually. So it is necessary to look for the therapeutic regimen with high performance and low hypotoxicity. Kanglaite, a kind of the traditional Chinese medicine from coicis semen, is an effective anti-cancer material. It can induce apoptosis, inhibit angiogenesis, therefore kill or inhibit the tumor cell. Recent years it has been used widespread in clinical tumor treatment. Some investigations confirmed that Kanglaite combined cisplatin and 5Fu can raise remission rate and clinical profit reaction rate. For this reason, we use Kanglaite combined Gemcitabine in pancreatic cancer treatment and invest the effect of two medicine on apoptosis and the expression of bcl 2, Bax and V EGF in pancreatic cancer cell and so as to provide a new method for pancreatic cancer treatment.

Kanglaite combined Gemcitabine inhibits growth of nude mouse subcir taneous transplantation tumor of human PC-3 pancreatic cancer cell.caj  Click to see details.

Kanglaite for treating advanced non-small-cell lung cancer

Bibliographic details: Zhu L, Yang Z, Wang S, Tang Y.  Kanglaite for treating advanced non-small cell lung cancer: a systematic review. Chinese Journal of Lung Cancer 2009; 12(3): 208-215


In the past years, many reports on Kanglaite were publicated in China, researchers across the country. The aim of this study is to review the effectiveness and safety of Kanglaite for treating advanced non-small cell lung cancer.


Authors searched the Cochrane Library, Pubmed, Embase, Cancerlit, CBM, CNKI and VIP. Mannual and additional search were also conducted. All randomized controlled trials/quasi-RCT comparing Kanglaite with other lung cancer treatment were included. Two reviewers independently performed data extraction and appraised the publications using the Juni instrument, disagreements were resolved by consensus. Double data were entered and analyzed by RevMan 4.2 software are by Cochrane Collaboration.


Sixteen reports were included in the meta-analysis. The quality of 16 studies was low. Pooling data of 5 studies indicated that the effect of Kanglaite+NP (Vinorelbine+Cisplatin) was better than NP with RR 1.46, 95% Confidence Interval 1.13 to 1.91. Pooling data of 3 studies of MVP (Mitomycin+Vindsine+ Cisplatin) plus Kanglaite indicated that the effect was better with RR 1.84, 95%CI 1.22 to 2.76. Pooling data of 2 studies showed that the effect of GP (Gemcitabine+Cisplatin) plus Kanglaite was better than GP with RR 1.63, 95%CI 1.09 to 2.43. Fourteen studies revealed that Kanglaite may reduce the side-effect induced by regular treatment. Ten studies showed regular treatment plus Kanglaite can stabilite/improve quality of life.


Kanglaite can enhance clinical effect of regular treatment, reduce side-effect and stabilite/improve quality of life, but the effect of Kanglaite being used in clinical settings needs to be confirmed by further large and multicenter.